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Background: A previous meta-analysis reported on the mid-term outcomes of infrainguinal bypass grafts in patients with
critical limb ischemia and end-stage renal disease. Given the competing interest in endovascular procedures, the results of
bypass surgery must be assessed as precisely as possible for future comparison. In this study, the original meta-analysis was
refined and updated by increasing the number of studies reviewed, estimating primary graft patency, extending follow-up
time, and investigating the problem of early amputation despite a patent graft.
Methods: Studies published from 1987 through 2005 were identified from two electronic databases. Two investigators
independently extracted the survival data from life tables, survival curves, and texts. Pooled survival curves were then
constructed for graft patency, limb salvage, and patient survival according to a random-effects protocol for meta-analysis.
Results: Of 28 articles included, 18 reported amputation despite a patent graft in 84 (10%) out of 844 limbs, and 25
described a perioperative mortality of 88 (8.8%) out of 996 patients. The 5-year pooled estimate (SE) was 50.4% (15.4%)
for primary patency, 50.8% (19.0%) for secondary patency, 66.6% (11.2%) for limb salvage, and 23.0% (11.7%) for patient
survival. No publication bias was detected.
Conclusions: Limb salvage can be achieved in most end-stage renal disease patients who undergo bypass surgery for critical
ischemia, but survival is poor. To avoid early amputation despite a patent graft, bypass grafting should not be offered to
patients with a great amount of tissue loss or extensive infection. (J Vasc Surg 2007;45:536-42.)Widespread atherosclerosis is common in patients with
end-stage renal disease (ESRD), defined as the requirement
for renal replacement therapy. Because diabetes mellitus
and high blood pressure are risk factors common to both
diseases, it is not surprising that approximately 5% of ESRD
patients develop critical limb ischemia.1,2 Consequently,
some form of revascularization or primary amputationmust
be considered for these patients, who also have impaired
immunity, susceptibility to infection, and poor wound
healing.3,4 Given the competing interest in endovascular
procedures,1 the results of bypass surgery must be assessed
as precisely as possible for future comparison. A previous
meta-analysis of infrainguinal bypass grafts in ESRD pa-
tients that was published in 2001 estimated the graft
patency, limb salvage, and patient survival,2 but many other
reports have been published in the intervening period. For
this reason, this study aimed to refine and update that
meta-analysis by assessing primary and secondary patency
separately, obtaining more precise estimates for all of the
targeted outcomes, and extending the follow-up period.
Secondary objectives included an investigation of both
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536duplex scanning for graft surveillance and early amputation
despite a patent graft.
METHODS
Study search. An electronic search of the PUBMED
and EMBASE databases covering January 1, 1987, to De-
cember 31, 2005, was performed by using the descriptors
“end-stage renal disease” and “bypass.” Abstracts of articles
selected by title were read online to reduce the number of
articles for full-text examination. Finally, additional titles
were sought in the bibliographies of the retrieved articles.
Criteria for inclusion. The articles included satisfied
the following requirements: (1) patients with ESRD were
analyzed separately; (2) graft patency or limb salvage was
the outcome of interest; (3) survival analysis was used to
describe at least one outcome or sufficient data were pre-
sented that allowed the reconstruction of a life table; (4) a
follow-up period of 1 year or more, at least for some
patients; (5) publication in 1987 or later; and (6) no repeat
inclusion of patients. Whereas the original meta-analysis
included 16 articles,3-18 this update added another 12
articles19-30 (Table I). Two articles that included the same
10 patients were used to assess different outcomes.11,27
Data extraction. Two authors (M.A. and M.R.) ex-
tracted the data independently and resolved disagreements
by discussion on several occasions. The outcome measures
of interest were recommended standards that included
primary and secondary graft patency, limb salvage, and
patient survival.31 The survival data were extracted from 15
life tables, 44 survival curves that showed the number of
-analy
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survival curves that omitted the number at risk. The
survival data were also extracted from the text and an-
other source: either a life table or a survival curve describ-
ing a different outcome in 10 instances, from the text
alone in 14 instances, and from individual patient data in
4 instances. Authors of four articles kindly provided
additional information on request.19-22
Study quality. An ideal study should contain life ta-
bles rather than graphs, the 1-month follow-up, a 5-year
follow-up, no flat tails, and a report of primary and second-
ary patency, limb salvage, and patient survival. Also impor-
tant are a demographic profile linked to survival data, the
type of renal replacement therapy, the rate of previous
operation and tissue loss, a measurement of runoff, regi-
mens of postoperative anticoagulant therapy, the rate of
vein use, the rate of amputation despite a patent graft,
mention of the use of duplex scanning for graft surveillance,
and data on further procedures. Each of the preceding
items was graded as 1 or 0, so that a perfect study would
score 18.
Statistical methods. Random-effects meta-analysis
combined monthly rates of success from single series to
yield a pooled estimate of success for each month of follow-
up. The product of successive monthly pooled estimates of
success then yielded a pooled measure of cumulative suc-
Table I. Articles included in the updated meta-analysis
Author Year n m Pr
Edwards15 1988 19 25 
Chang18 1990 24 32 
Harrington5 1990 39 56 
Wasserman14 1991 37 37 
Sanchez6 1992 47 69 
Whittemore8 1993 12 16 
Lumsden16 1994 27 34 
Sakurai17 1995 11 14 
Baele7 1995 44 57 
Johnson4 1995 53 69 
Harpavat12 1998 20 25 
Peltonen11 1998 10 11 
Hakaim10 1998 23 25 
Leers3 1998 34 41 
Nicholas29 2000 57 66 
Treiman9 2000 11 11 
Korn13 2000 23 33 
Cox20 2001 63 78 
Lantis25 2001 60 78 
Meyerson24 2001 64 84 
Reddan21 2001 20 31 
Biancari27 2002 21 25 
Ramdev22 2002 146 177 
Kimura23 2003 22 33 
Wölfle26 2003 34 37 
Schwarzbach30 2004 36 50 
Georgopoulos28 2005 39 56 
Chambon19 2005 41 50 
n, Number of patients; m, number of bypasses; , not included in the metacess. Within-study and between-study variances, calculatedas previously reported,2 reduced the influence of study size
on the pooled estimates, and a standard error was calculated
for these estimates at selected intervals (Appendix). The
hazard rate or the instantaneous risk of an event (graft
failure, amputation, or death) was calculated at monthly
intervals to investigate the relationships between outcomes.
Sensitivity analysis. Sensitivity analysis was mostly re-
stricted to limb salvage because this outcome was more
relevant than graft patency, did not depend on the type of
patency reported, and was described in more articles. Fun-
nel plots were used to assess publication bias, and the effects
of a fixed-effects model of meta-analysis, which assumes
null between-study variances, were also investigated. To
better investigate the relationship between any two out-
comes, the articles that did not report both of the outcomes
were excluded. Finally, studies that contained inflow pro-
cedures alone were excluded.
RESULTS
Characteristics of the original studies. This update
of 28 articles included 1314 procedures performed in 1272
lower limbs of 1027 patients, of whom 964 were dialysis
dependent, 58 had a renal transplant, and 5 had renal
insufficiency not necessitating dialysis. There were 1285
infrainguinal surgical procedures (bypasses, 99%; other,
1%), 14 axillofemoral bypasses, 2 aortofemoral bypasses, 5
raft patency
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28 studies, but only 14 of these reported all of the out-
comes. Demographic and surgical variables of interest were
reported in most articles (Table II), but only three articles
reported a measure of runoff. The number of articles that
contributed at least 1 series to follow-up was 22 (81%) at 2
years, 16 (59%) at 3 years, 10 (37%) at 4 years, and 7 (26%)
at 5 years. The average follow-up time ranged 5.5 to 27
months (median, 12 months).
Limb salvage was reported in all but one article,
whereas primary patency was omitted in 7 articles (274
patients), secondary patency was omitted in 8 articles
(250 patients), and patient survival was omitted in 4
articles (95 patients). Only 5 studies with a total of 257
grafts (vein, n  243; prosthetics, n  14) used graft
surveillance with duplex scanning routinely and also
assessed primary and secondary patency. The rate of limb
salvage at 1 year varied widely among the studies (Fig 1),
and only two studies did not show a flat tail for at least one
outcome. Eighteen articles reported amputation despite a
patent graft for 84 (10%) of 844 limbs, whereas 25 articles
described a perioperative mortality of 88 (8.8%) of 996
patients.
Main outcomes. The pooled estimates of the targeted
outcomes are shown in Table III. T h e difference between
primary and secondary patency was 6.0% or less at all
yearly intervals but reached a maximal value of 7.8% at 30
months (Fig 2). There was an absolute decrease in the
crude rate of graft failure of 5.1% for 18 studies that
assessed both types of patency and 10.1% for five of these
studies that used graft surveillance with duplex scanning
routinely. When the latter studies were pooled, the maxi-
mal difference between primary and secondary patency
became 12.6% at 36 months. In a graphical display of
pooled survival curves (Fig 2), primary patency and patient
survival were almost identical up to 7months, but the curve
for the latter decreased much faster thereafter.
During the first 2 years of follow-up, the difference in
the hazard rates for amputation and loss of secondary
Table II. Covariates at the study level in 28 studies
included in the updated meta-analysis
Variable Median Range Missing data
No. patients 34 10-146
No. procedures 39 11-177
Publication year 1999 1988-2005
Score of quality 10 4-13
Mean age (y) 63 45-67 3
Women (%) 41 12-56 5
Diabetes (%) 80 55-100 2
Smokers (%) 39 0-74 7
Claudication (%) 0 0-12 2
Rest pain (%) 20 0-67 5
Tissue loss (%) 79 33-100 4
Infrapopliteal bypass (%) 69 7-100 5
Vein use (%) 85 43-100 5patency was 2.9% (7.5% vs 4.6%) in the first month, lessthan 1.0% up to 9 months, and predominantly negative in
the remaining 15 months (Fig 3). Consequently, the curve
for limb salvage crossed the curve for secondary patency to
occupy a higher position at 2 years and beyond.
In the studies reviewed, the 1-year limb salvage rates
correlated weakly with the rates of black patients (r 
0.37), distal anastomosis at the popliteal artery (r  0.33),
and vein use (r0.38); the rates of amputation despite a
patent graft correlated weakly with the rates of black pa-
tients (r 0.49), diabetic patients (r 0.45), and vein use
(r 0.48). In the updated meta-analysis, the 1-year pooled
limb salvage for eight studies that used duplex scanning for
graft surveillance routinely did not differ importantly from
the remaining studies that used this tool less frequently or
omitted the strategy adopted (68.8% vs 64.9%).
Sensitivity analysis. A modified funnel graph was
symmetrical for a study size of less than 30, thus indicating
that there was no publication bias, at least for limb salvage
(Fig 4); in addition, the 5-year pooled limb salvage in-
creased from 66.6% to 69.7% when a fixed-effects model of
meta-analysis was used. With regard to the relationship
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Fig 1. One-year limb salvage in 28 studies (circles) and in the
updated meta-analysis (diamond). Bars indicate the 95% confi-
dence interval.
Table III. Meta-analysis estimates of graft patency, limb
salvage, and patient survival
Month
Primary
patency
Secondary
patency
Limb
salvage
Patient
survival
1 94.2 (1.8) 95.4 (1.5) 92.5 (1.6) 95.2 (1.8)
3 88.2 (2.2) 91.0 (2.1) 88.7 (1.9) 89.6 (1.0)
6 81.4 (3.2) 87.8 (2.8) 84.2 (2.3) 82.7 (1.0)
12 74.9 (3.1) 80.9 (2.5) 78.6 (2.6) 71.6 (1.2)
24 69.8 (4.5) 74.6 (3.9) 74.7 (3.7) 53.3 (4.1)
36 60.8 (6.6) 66.6 (7.3) 69.3 (5.8) 41.0 (5.1)
48 55.6 (9.6) 57.6 (12.7) 66.6 (7.4) 32.5 (8.7)
60 50.4 (15.4) 50.8 (19.0) 66.6 (11.2) 27.5 (11.7)
Values are pooled estimates (SE).between outcomes, the difference between primary and
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months, whereas the crossing point of the survival curves
for limb salvage and secondary patency moved from 24 to
18 months. When five studies that contained inflow proce-
dures alone were excluded, the 5-year estimate of limb
salvage increased by 0.8%.
DISCUSSION
This updated meta-analysis more than doubled the
number of procedures and patients included in the original
meta-analysis and extended the length of follow-up from 2
to 5 years. Moreover, the methods used were refined by
summarizing primary and secondary patency separately and
using pooled survival curves for the main outcomes. Be-
cause flat tails in the pooled survival curves overestimated
graft patency and limb salvage in the long run, it would be
better to examine the 4-year results.
The use of primary and secondary patency yieldedmore
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Fig 2. Pooled survival curves of primary (gray) and secondary
(black) graft patency, limb salvage (red), and patient survival
(blue).
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Fig 3. Hazard rates for amputation (open circles) and loss of
secondary patency (full circles).reliable estimates of graft function than in the originalmeta-analysis, in which primary patency was not studied
and secondary patency was clearly defined in only 10 of the
16 studies. The updated pooled estimates of early graft
patency were similar to the rates obtained for non-ESRD
patients,5,23-25 possibly because skilled surgeons were in-
volved and because an autogenous vein was used in 85% of
the reconstructions.
The close proximity between the pooled curves of
primary and secondary patency indicated that revision of
failing or failed grafts was uncommon or often unsuccess-
ful. Indeed, when the small subgroup of five studies that
used duplex scanning for graft surveillance routinely was
compared with Mills and Taylor’s32 report of non-ESRD
patients, there was little difference between the crude rates
of graft failure, 10.1% vs 9.1%, and in the pooled patency at
36 months, 12.6% vs 16%, respectively. Although a limited
use of duplex scanning for graft surveillance plausibly ex-
plains the proximity between the pooled curves of graft
patency, a poor health condition or limb status discourag-
ing graft revision cannot be neglected.1
The pooled limb salvage at 2 years was 73.0% (4.3%) in
the original meta-analysis vs 74.7% (3.7%) in the updated
meta-analysis, with little change in the pooled estimate and
a small gain in precision. As for secondary patency, it was
reasonable to expect higher pooled estimates of limb sal-
vage in the updated meta-analysis. Perhaps a more rigorous
selection of patients obscured some improvement in surgi-
cal management. Indeed, this update compared with the
original meta-analysis showed a slightly higher median
value for mean age (63 vs 58.5 years) and for the prevalence
rates of both diabetes mellitus (80% vs 73%) and prosthetic
grafts (15% vs 12%). A comparison of the hazard rates for
amputation and loss of secondary patency showed that
major amputation despite a patent graft occurred predom-
inantly in the short-term follow-up. This finding was in
contrast to non-ESRD patients, for whom the limb salvage
rate usually outweighs the secondary patency rate during
the entire follow-up.18,24 Hence, when treating ESRD
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Fig 4. A funnel graph symmetric around the pooled estimate
(vertical line) for study size less than 30 did not indicate the
presence of publication bias.patients, the potentials of bypass surgery in achieving he-
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emia, must be tempered by the high rates of perioperative
death and early amputation despite a patent graft. Accord-
ing to Walsh,33 bypass surgery in ESRD patients should be
contemplated only when every condition is optimal, ie, the
best vein, the best skin, and the best sort of everything. This
means that revascularization should not be considered for
patients with forefoot and deep heel defects or extensive
infection.6,13,22,26
Although more clinically relevant than graft patency,
limb salvage overestimates the potentials of surgical revas-
cularization because a salvaged limb may still show signs
and symptoms of critical ischemia, severe diabetic neurop-
athy, or extensive infection, thereby reducing patient ben-
efit.17 Notably, Nicholas et al29 reported rates of indepen-
dent ambulation of 56% and 10% at 1 year for patients
without and with ESRD, respectively, whereas for patients
with ESRD Harpavat et al12 reported ambulation of some
level for 61% and Korn et al13 reported sustained benefit for
45% at 1 year. With regard to amputation-free survival, the
difference between survival and amputation-free survival
was 6% or less at 1 year.26,27 Measures of the quality of life
in non-ESRD patients have indicated that infrainguinal
revascularization is superior to primary amputation,34 but
this i s less certain for ESRD patients.17,20,21 Because the
benefit of surgical revascularization may be modest for
ESRD patients, several authors have recognized a role
for primary amputation when tissue loss is exten-
sive.3,6,13-15,25-27 Conversely, modern techniques of
skin coverage have been used with moderate success in
selected patients.3,35
The remarkable similarity between the pooled curves of
primary patency and patient survival up to 7 months sug-
gested that the loss of primary patency possibly contributed
to death during this interval. However, this remains spec-
ulative because the studies considered here reported only
the final causes of death, with the notable exception of
Sanchez et al,6 who reported graft complication leading to
death in 3 (23%) of 13 early deaths. In any case, the
perioperative mortality was not negligible (5.1% in the
updated meta-analysis, but 8.8% in the summation analy-
sis). A recent survey has shown a perioperative mortality of
12.6% for 508 bypasses and 7.7% for 292 angioplasties, but
the ESRD patients in these 2 groups may not have been
strictly comparable.1 Because mortality is the major prob-
lem for ESRD patients with critical ischemia and because
angioplasty likely reduces early mortality, this procedure
may extend revascularization to less compromised patients,
replace or complete surgical revascularization, and be used
in a last attempt before amputation.27,36 However, the final
utility of angioplasty in improving limb salvage remains
uncertain.33
In strong support of the inferences from this updated
meta-analysis, the study design was compatible with real life
and allowed an adequate sampling of a hypothetical popu-
lation of studies. Moreover, the studies were reviewed in
sufficient number, adopted similar outcomes, and reported
high response rates. Finally, the comparisons of primaryand secondary patency, as well as the comparisons between
limb salvage and secondary patency, were robust in sensi-
tivity analysis.
Most of the limitations in this study were attributable
to the nonrestrictive inclusion criteria adopted. Often, the
individual articles reported outcomes selectively, did not
use standard patencies, described a short follow-up time,
omitted losses to follow-up, or showed a flat tail in the
survival curves. In addition, it was not possible to investi-
gate amputation-free survival, functional status, or any
aspect of quality of life. These problems were not com-
pletely overcome.
In conclusion, limb salvage can be achieved in most
ESRD patients who undergo bypass surgery for chronic
critical limb ischemia, but survival is poor. To avoid early
amputation despite a patent graft, bypass grafting should
not be offered to patients with a great amount of tissue loss
or extensive infection.
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APPENDIX: STATISTICAL NOTES
The strategy. We constructed a strategy to combine
survival data because different grids of time intervals had
been used in the series reviewed. In the first step, we
redistributed in equal quantities at 1-month intervals the
units of analysis censored at intervals greater than 1 month.
A unit of analysis was a graft, a limb, or a patient. This
approach assumed constant hazard rates within long time
intervals and the midpoint of such intervals as the survival
time for censored units, as is usual in actuarial survival
analysis. Next, we obtained the numbers of failed units for
intervals of 1 month by using the units at risk at the start of
an interval, the redistributed censored units, and the inter-
val hazard rate. We then calculated the Kaplan-Meier suc-
cess rate for each series and each month of follow-up and
used this rate as the treatment effect.
In the second step, we calculated a within-series vari-
ance (s2) for each monthly success rate in each series; next
we calculated a between-series variance (2) for each
month. To obtain pooled measures of treatment effect for
eachmonth of follow-up, we used in the third step random-
effects modeling, which assumes that studies at hand are
independent and equally distributed. Finally, the product
of successive monthly pooled measures of treatment effect
allowed us to estimate the survival function and to calculate
approximate standard errors.
The statistical problem. Because this meta-analysis
dealt with case series, our primary problem was one of
estimation, not hypothesis testing. Consequently, we esti-
mated survival functions and calculated standard errors for
primary and secondary patency, limb salvage, and patient
survival.
Survival probability in each month. For each series i
and each month j of follow-up, the estimated survival
probability, ij, was determined as follows:
ij 1 fij ⁄ nij,
where fij is the number of failed units and nij is the number
of units at risk.
Within-series variance. The within-series variance,
sij
2, was obtained as follows:
Sij2 nij (nij 2)2 ⁄ [(fij 1)(nij fij 1)]
Between-series variance. For each month j, the
between-series variance, j
2, was calculated as follows:
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2 [ni·(i·mj)2] ⁄ [(kj 1)] ⁄ kj ni·],
where, in the target month j, i. is the estimated survival
probability in study i, mj is the average for i., ni. is the
number of units at risk, and kj is the number of series
available.
Weighting and combining the ij. Let wij be the
weight attributed to each ij. When using random-effects
modeling, it follows that
Wij 1 ⁄ (Sij2 j2)
A value for the survival function in month j, Lj, was ob-
tained as follows:
Lj (i·wi·) ⁄ wi· ,
where i. is the estimated survival probability in the target
month j, and wi. is the weight attributed to i..
Such estimators L will be consistent and approximatelyj
normal and are derived on the basis of the fact that theestimators for each series are approximately normal with an
estimable variance. Finally, the product of successive Lj
yielded Gj, the estimated survival probability at month j.
Variance for Gj. After they were properly corrected,
Kaplan-Meier estimates and their respective variances in the
individual series were used to obtain the variance of Gj. This
was performed by using again random-effects modeling in a
way similar to that of obtaining Lj. The difference was that
Peto’s within-series variances in study i at month j and j
2
were summed up to weigh the Kaplan-Meier estimates at
month j. A summary Kaplan-Meier estimate, Kj, and its
variance, V{Kj}, were thus obtained for month j. Because Kj
and Gj differed a little, the variance of Gj, V{Gj}, was
obtained as follows:
VGj VKj[Lj(1 Lj
2)] ⁄ [Kj(1 Kj2)]The standard error for Gj was the square root of V{Gj}.
